G7 Therapeutics AG, sold and renamed 2017
Pharmaceuticals - Schlieren, Zurich, Switzerland
G7 Therapeutics AG, sold and renamed 2017 Employees
G7 Therapeutics AG, sold and renamed 2017 Details
G7 Therapeutics (renamed in January 2017 to Heptares Therapeutics Zurich AG, Schlieren) utilises proprietary approaches to stabilise G protein-coupled receptors (GPCRs) and enables novel structure-based drug development strategies to be applied for the design of highly selective small molecules or biologics targeting GPCRs.We are a wholly owned subsidiary of Heptares Therapeutics, located in Zurich, Switzerland, realising the potential of stabilised GPCRs for the design of novel medicines. We are focused on stabilising GPCRs to be fed into the exclusive drug development pipeline at Heptares Therapeutics. Innovation, passion and reliability are our leitmotifs to exploit novel therapeutic agents that address unmet medical needs.
G7 Therapeutics AG, sold and renamed 2017 Technologies
Load Balancers
Nginx
Fonts
Google Font API
Other
Mobile Friendly
Analytics and Tracking
StatCounter
CSS and JavaScript Libraries
Bootstrap Framework